Participants’ DNA samples were genotyped using the Illumina Human1M array (Illumina, San Diego, CA), the Illumina Human OmniExpress 12V1 array (Illumina), the Illumina 2.5M array (Illumina) or the Smokescreen genotyping array (Biorealm LLC, Walnut, CA; Baurley et al. 2016). A detailed description of data processing, quality control, and imputation is available elsewhere (Lai et al. 2019). Data were imputed to 1000 Genome Phase 3, and single nucleotide polymorphisms (SNPs) with a genotyping rate < 0.95, that violated Hardy-Weinberg equilibrium (p < 10−6), or had minor allele frequency (MAF) < 0.01 were excluded from analysis.
